NCT05577585 Ketamine in OCD: Efficacy and Effects on Stress and Cognition
| NCT ID | NCT05577585 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of Vienna |
| Condition | Obsessive-Compulsive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2022-10-01 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2022-10-01 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main goal of this trial is to demonstrate therapeutic efficacy of low dose ketamine in patients with OCD. We expect that ketamine will alleviate symptoms in the hours following application, but also - if effective - that the anti-OCD effects might last for several days after a single infusion.
Eligibility Criteria
Inclusion Criteria: * Primary diagnosis of obsessive-compulsive disorder * A score of 16 or higher on the Yale-Brown Obsessive Compulsive Scale and ability to provide written informed consent * At least one previous treatment for OCD Exclusion Criteria Experimental Group: * Any history of current or past psychotic disorder * A manic episode within the preceding three years * Current or unstable remitted substance abuse or dependence except nicotine * Pregnancy or elevated risk of becoming pregnant during study duration (desire to have children) and refusal to utilize a proper method of contraception * Any current severe personality disorder except comorbid anankastic personality disorder * Morbus Raynaud * Inability to follow the study protocol or adhere to operational requirements * Current and unstable suicidality * Unstable hypertension * Untreated hyperthyroidism * Any unstable cardiovascular disease * Untreated disorders severely affecting the HPA-axis (M.Addison, M.Cushing) * Current pharmacological therapy severely affecting the HPA-axis like corticosteroids or ACTH Exclusion Criteria Treatment as Usual Group: * Any history of current or past psychotic disorder * A manic episode within the preceding three years * Current or unstable remitted substance abuse or dependence except nicotine * Any current severe personality disorder except comorbid anankastic personality disorder * Current and unstable suicidality
Contact & Investigator
Christoph Kraus, MD PhD
PRINCIPAL INVESTIGATOR
Medical University of Vienna, Department of Psychiatry and Psychotherapy
Frequently Asked Questions
Who can join the NCT05577585 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Obsessive-Compulsive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05577585 currently recruiting?
Yes, NCT05577585 is actively recruiting participants. Contact the research team at christoph.kraus@muv.ac.at for enrollment information.
Where is the NCT05577585 trial being conducted?
This trial is being conducted at Vienna, Austria.
Who is sponsoring the NCT05577585 clinical trial?
NCT05577585 is sponsored by Medical University of Vienna. The principal investigator is Christoph Kraus, MD PhD at Medical University of Vienna, Department of Psychiatry and Psychotherapy. The trial plans to enroll 60 participants.